Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry

[1]  M. Kurosumi,et al.  Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study , 2015, Breast Cancer.

[2]  J. Hopper,et al.  Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Keda Yu,et al.  Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis , 2013, BMC Cancer.

[4]  F. Couch,et al.  Classification of missense substitutions in the BRCA genes: A database dedicated to Ex‐UVs , 2012, Human mutation.

[5]  J. Lee,et al.  Does Immediate Breast Reconstruction after Mastectomy affect the Initiation of Adjuvant Chemotherapy? , 2011, Journal of breast cancer.

[6]  C. Isaacs,et al.  BRCA Mutation Testing in Determining Breast Cancer Therapy , 2011, Cancer journal.

[7]  Jennifer D. Brooks,et al.  Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status , 2011, Breast Cancer Research and Treatment.

[8]  O. Olopade,et al.  Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers , 2011, British Journal of Cancer.

[9]  S. Fox,et al.  Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry , 2011, Breast Cancer Research.

[10]  L. Lostumbo,et al.  Prophylactic mastectomy for the prevention of breast cancer. , 2010, Cochrane Database of Systematic Reviews.

[11]  Hoda Anton-Culver,et al.  Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Griffith,et al.  Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy , 2010, Breast Cancer Research and Treatment.

[13]  C. Begg,et al.  Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer , 2010, Breast Cancer Research and Treatment.

[14]  U. Bick,et al.  Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Whittemore,et al.  BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research , 2009, Breast Cancer Research and Treatment.

[16]  J. Klijn,et al.  Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. , 2007, European journal of cancer.

[17]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[18]  L. V. van't Veer,et al.  Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers , 2005, British Journal of Cancer.

[19]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[21]  B. Emami,et al.  Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. , 2003, International journal of radiation oncology, biology, physics.

[22]  F. V. van Leeuwen,et al.  Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. , 2003, Journal of the National Cancer Institute.

[23]  E. McDermott,et al.  Hereditary breast cancer , 1997, The British journal of surgery.

[24]  M. Piccart,et al.  Adjuvant systemic therapy for breast cancer. , 1995, Current opinion in oncology.

[25]  F. Meric-Bernstam.  High Risk of Contralateral Breast Carcinoma in Women With Hereditary/Familial Non-BRCA1/BRCA2 Breast Carcinoma , 2007 .

[26]  J. Klijn,et al.  Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients , 2005, Breast Cancer Research and Treatment.